TDN-345 is a Ca²⁺ antagonist primarily used in research on vascular diseases and age-related dementia, such as Alzheimer's disease; it induces nerve growth factor (NGF) synthesis and secretion in vitro (ED₅₀ = 0.88 μM); in vivo, it dose-dependently reduces mortality and ischemic neurological deficit scores when administered orally before and after cerebral ischemia, and decreases stroke mortality and recurrence in stroke-prone spontaneously hypertensive rats (SHRSP) when given once daily for three weeks post-stroke.